Home
>
National Drug Code (NDC)
>
Cilostazol
Cilostazol - 0093-2064-50 - (Cilostazol)
Drug Information of Cilostazol
| Product NDC: | 0093-2064 |
| Proprietary Name: | Cilostazol |
| Non Proprietary Name: | Cilostazol |
| Active Ingredient(s): | 100 mg/1 & nbsp; Cilostazol |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Cilostazol
| Product NDC: | 0093-2064 |
| Labeler Name: | Teva Pharmaceuticals USA Inc |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA077027 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20121024 |
Package Information of Cilostazol
| Package NDC: | 0093-2064-50 |
| Package Description: | 5000 TABLET in 1 BOTTLE (0093-2064-50) |
NDC Information of Cilostazol
| NDC Code | 0093-2064-50 |
| Proprietary Name | Cilostazol |
| Package Description | 5000 TABLET in 1 BOTTLE (0093-2064-50) |
| Product NDC | 0093-2064 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Cilostazol |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 20121024 |
| Marketing Category Name | ANDA |
| Labeler Name | Teva Pharmaceuticals USA Inc |
| Substance Name | CILOSTAZOL |
| Strength Number | 100 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Phosphodiesterase 3 Inhibitor [EPC],Phosphodiesterase 3 Inhibitors [MoA] |
